Cosmo Delivers Strong Performance in H1 2025, Raises Full-Year EBITDA Guidance and Accelerates Recurring Revenue Growth Across AI and Dermatology

Globe and Mail

19 hours ago

Ad hoc announcement pursuant to Art. 53 LR
EBITDA guidance raised by €4.5M as Cosmo executes on its Vision 2030 strategy; H1 Recurring Revenues from GI Genius™ up 128%, Winlevi® up 23%; Investors Call today at 2 pm CET.
Dublin, Ireland--(Newsfile Corp. - July 23, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today reported strong half-year results for 2025, underscoring the Company's strategic execution, commercial momentum, and capital discipline across its key growth platforms.
On the back of robust performance in H1 2025, Cosmo has raised its full-year EBITDA guidance by €4.5 million and reconfirmed its total revenue outlook for 2025, while confirming double-digit growth in recurring revenues – driven by its leading products and technologies in MedTech AI and Dermatology.
H1 2025 Highlights
Cosmo delivered strong financial and operational performance in the first half of 2025, with strong momentum in GI Genius™ and Winlevi®, continued cost discipline, and a strong balance sheet.
Total Revenues: €51.7 million
€41.9 million in recurring revenues
€9.8 million in project-based revenues
Growth Drivers:
GI Genius™ recurring revenues: +128% YoY
Winlevi® recurring revenues: +23% YoY
Operating Expenses: €57.8 million
Cost of Sales: €25.6 million (+10% YoY)
R&D: €18.0 million (–6% YoY)
SG&A: €14.3 million (–13% YoY)
Cash, Equivalents, and Investments: €133.3 million as of June 30, 2025
Treasury Shares: 1.6 million shares held as of June 30, 2025 (~€97.7 million), an increase of 76.2K shares vs. December 31, 2024
H2 2025 Outlook
Cosmo expects continued momentum in the second half of 2025, with:
Recurring revenues: €43 – 48 million
Continued triple digit growth from GI Genius®, double digit growth from Winlevi® and steady growth from Gastro and CDMO business.
Increased R&D spending to advance Phase II programs for Bile Acid Diarrhoea and Distal Ulcerative Colitis.
Continued SG&A discipline to drive margin expansion
Strategic Context
Cosmo operates at the intersection of high-growth global markets — AI in endoscopy, Dermatology, Gastrointestinal diseases, and advanced Drug Manufacturing.
Each of these sectors is fuelled by large, persistent clinical unmet needs:
In MedTech AI, Cosmo's GI Genius™ is redefining detection and diagnostic accuracy in real time.
In Dermatology, Winlevi® is the first new acne mechanism of action in decades.
In Gastroenterology, Cosmo's Phase II pipeline addresses conditions like Bile Acid Diarrhoea and distal ulcerative colitis.
In CDMO, Cosmo supports global pharmaceutical partners with advanced formulation, regulatory, and sterile manufacturing expertise.
What makes Cosmo unique is its ability to scale innovation across all four businesses — leveraging common R&D infrastructure, regulatory know-how, Artificial Intelligence, Digital capabilities, and manufacturing excellence. This integrated model is designed to unlock operational leverage, reduce time-to-market, and drive compounding long-term growth.
Giovanni Di Napoli, Chief Executive Officer of Cosmo, commented:
'These results validate our strategy: we are scaling impact across high-need therapeutic areas with real momentum. What sets Cosmo apart is our ability to operate as one company with four powerful platforms: AI-powered MedTech, next-generation Dermatology, GI innovation, and high-value CDMO. These aren't isolated businesses, they reinforce each other, creating a scalable ecosystem with clinical, operational, and financial synergies. We're not just growing — we're compounding. And this is just the beginning of our 2030 vision.'
Svetlana Sigalova, Chief Financial Officer of Cosmo, added:
'Our first-half results reflect strong execution, continued growth in recurring revenues, and prudent financial management. We remain disciplined in controlling costs and investing where it matters most. With a solid balance sheet and clear capital priorities, we're well positioned to support Cosmo's long-term growth and deliver on our 2030 ambition.'
Analyst, media and investors call today at 2 pm CET
Cosmo invites investors, financial analysts and business/life sciences journalists to a live webcast presentation which will follow today at 2:00 pm CET.
To join via Web browser, click here
To join via phone, please use one of the following dial-in numbers:
Switzerland/Europe [phone]
United Kingdom [phone]
United States [phone]
Key figures
EUR 1'000
H1 2025
H1 2024
(restated)
Income statement
Revenue
51,720
136,237
Recurring Revenues
41,925
42,379
Project Based Revenues
9,795
93,858 [1]
Cost of sales
(25,571)
(23,150)
Gross profit
26,149
113,087
Other income
4,701
1,122
R&D costs
(17,997)
(19,137)
SG&A costs
(14,264)
(16,323)
Net operating expenses
(27,560)
(34,338)
Operating profit/(loss)
(1,411)
78,749
Net financial income
741
1,794
Profit/(loss) before taxes
(670)
80,543
Profit/(loss) after taxes for the period
(2,030)
71,177
EBITDA
4,852
84,868
Statement of financial position
As of 30 June 2025
As of 31 December 2024
Non-current assets
423,104
444,514
Cash and cash equivalents
50,749
44,296
Other current assets
136,477
157,962
Liabilities
143,354
141,681
Equity attributable to owners of the Company
460,239
498,330
Non-controlling interests
6,737
6,761
Equity ratio (%)
75.4%
77.0%
Shares
H1 2025
H1 2024
(restated)
Weighted average number of shares
15,970,541
16,105,126
Earnings/(loss) per share (in EUR)
(0.126)
4.423
The full Half-Year 2025 Report of Cosmo can be found for download as pdf-document on the Company's website via https://www.cosmopharma.com/investors/financial-reports
About Cosmo
Cosmo is a life sciences company focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). We design, develop, and manufacture advanced solutions that address critical medical needs and raise the standard of care. Our technologies are trusted by leading global pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. Guided by our purpose - Building Health Confidence - our mission is to empower patients, healthcare professionals, and partners by innovating at the intersection of science and technology. Founded in 1997, Cosmo is headquartered in Dublin, Ireland, with offices in San Diego (USA), and in Lainate, Rome, and Catania (Italy). For more information, visit https://www.cosmohealthconfidence.com
Financial calendar
Attachments
PDF - English